Logo image of TIL

INSTIL BIO INC (TIL) Stock Fundamental Analysis

USA - NASDAQ:TIL - US45783C2008 - Common Stock

19.4 USD
+0.4 (+2.11%)
Last: 10/24/2025, 8:00:01 PM
19.1 USD
-0.3 (-1.55%)
After Hours: 10/24/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, TIL scores 2 out of 10 in our fundamental rating. TIL was compared to 534 industry peers in the Biotechnology industry. While TIL seems to be doing ok healthwise, there are quite some concerns on its profitability. TIL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TIL has reported negative net income.
In the past year TIL has reported a negative cash flow from operations.
In the past 5 years TIL always reported negative net income.
In the past 5 years TIL always reported negative operating cash flow.
TIL Yearly Net Income VS EBIT VS OCF VS FCFTIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

With a decent Return On Assets value of -36.59%, TIL is doing good in the industry, outperforming 62.17% of the companies in the same industry.
TIL's Return On Equity of -64.18% is fine compared to the rest of the industry. TIL outperforms 60.67% of its industry peers.
Industry RankSector Rank
ROA -36.59%
ROE -64.18%
ROIC N/A
ROA(3y)-40.76%
ROA(5y)-31.96%
ROE(3y)-58.04%
ROE(5y)-43.06%
ROIC(3y)N/A
ROIC(5y)N/A
TIL Yearly ROA, ROE, ROICTIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

TIL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TIL Yearly Profit, Operating, Gross MarginsTIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for TIL has been increased compared to 1 year ago.
Compared to 5 years ago, TIL has less shares outstanding
The debt/assets ratio for TIL is higher compared to a year ago.
TIL Yearly Shares OutstandingTIL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TIL Yearly Total Debt VS Total AssetsTIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

TIL has an Altman-Z score of -3.19. This is a bad value and indicates that TIL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.19, TIL is in line with its industry, outperforming 44.94% of the companies in the same industry.
A Debt/Equity ratio of 0.64 indicates that TIL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.64, TIL is not doing good in the industry: 73.22% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Altman-Z -3.19
ROIC/WACCN/A
WACCN/A
TIL Yearly LT Debt VS Equity VS FCFTIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 14.97 indicates that TIL has no problem at all paying its short term obligations.
TIL has a Current ratio of 14.97. This is amongst the best in the industry. TIL outperforms 90.07% of its industry peers.
TIL has a Quick Ratio of 14.97. This indicates that TIL is financially healthy and has no problem in meeting its short term obligations.
TIL has a better Quick ratio (14.97) than 90.07% of its industry peers.
Industry RankSector Rank
Current Ratio 14.97
Quick Ratio 14.97
TIL Yearly Current Assets VS Current LiabilitesTIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.86% over the past year.
EPS 1Y (TTM)29.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TIL will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.17% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.32%
EPS Next 2Y3.82%
EPS Next 3Y8.17%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TIL Yearly Revenue VS EstimatesTIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2029 2030 2031 2032 100M 200M 300M 400M
TIL Yearly EPS VS EstimatesTIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TIL. In the last year negative earnings were reported.
Also next year TIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TIL Price Earnings VS Forward Price EarningsTIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TIL Per share dataTIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.82%
EPS Next 3Y8.17%

More info and screens

0

5. Dividend

5.1 Amount

TIL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INSTIL BIO INC

NASDAQ:TIL (10/24/2025, 8:00:01 PM)

After market: 19.1 -0.3 (-1.55%)

19.4

+0.4 (+2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners69.66%
Inst Owner Change-1.15%
Ins Owners4.55%
Ins Owner Change0%
Market Cap130.95M
Revenue(TTM)N/A
Net Income(TTM)-84510000
Analysts82.5
Price Target69.02 (255.77%)
Short Float %14.14%
Short Ratio6.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.76%
Min EPS beat(2)-65.34%
Max EPS beat(2)-28.19%
EPS beat(4)1
Avg EPS beat(4)-28.95%
Min EPS beat(4)-66.31%
Max EPS beat(4)44.04%
EPS beat(8)3
Avg EPS beat(8)-67.75%
EPS beat(12)6
Avg EPS beat(12)-55.26%
EPS beat(16)6
Avg EPS beat(16)-43.78%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-29.33%
PT rev (3m)-42.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.96%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 0.99
EV/EBITDA N/A
EPS(TTM)-12.92
EYN/A
EPS(NY)-10.5
Fwd EYN/A
FCF(TTM)-8.84
FCFYN/A
OCF(TTM)-7.36
OCFYN/A
SpS0
BVpS19.51
TBVpS19.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.59%
ROE -64.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.76%
ROA(5y)-31.96%
ROE(3y)-58.04%
ROE(5y)-43.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.97
Quick Ratio 14.97
Altman-Z -3.19
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)707.89%
Cap/Depr(5y)4754.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.48%
EPS Next Y-8.32%
EPS Next 2Y3.82%
EPS Next 3Y8.17%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.38%
OCF growth 3YN/A
OCF growth 5YN/A

INSTIL BIO INC / TIL FAQ

What is the ChartMill fundamental rating of INSTIL BIO INC (TIL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TIL.


What is the valuation status of INSTIL BIO INC (TIL) stock?

ChartMill assigns a valuation rating of 0 / 10 to INSTIL BIO INC (TIL). This can be considered as Overvalued.


Can you provide the profitability details for INSTIL BIO INC?

INSTIL BIO INC (TIL) has a profitability rating of 1 / 10.


What is the financial health of INSTIL BIO INC (TIL) stock?

The financial health rating of INSTIL BIO INC (TIL) is 4 / 10.